Transgenomic : Investor Relations

November 1, 2001 – Please note that the command performance telephone number was listed incorrectly in our press release. The number to use for the conference call replay is 402-220-0665. We apologize for any inconvenience.
– Investor Relations

Transgenomic, Inc. Invites You to Join Its Third Quarter 2001 Conference Call on the Web

SAN JOSE, Calif., and OMAHA, Neb. (Oct. 19) -- In connection with Transgenomic, Inc.'s reporting of third quarter financial results, you are invited to listen to its conference call to be broadcast live over the Internet on Wednesday, October 31 at 5 p.m., Eastern time, with Collin D'Silva, chief executive officer. Transgenomic (Nasdaq: TBIO) will release its financial results on Wednesday, October 31 at 4 p.m. ET.

What:	Transgenomic's Third Quarter 2001 Financial Results Conference Call
When:	Wednesday, October 31, 2001, 5 p.m. ET
Where:	http://www.videonewswire.com/event.asp?id=1709
How:	Live over the Internet; simply log on to the web at the address above
Contact:	Mitchell L. Murphy, Investor Relations, Transgenomic, 402-452-5437

Future release of quarterly financial results and conference calls will be scheduled with similar timing, on the fifth Wednesday after the end of each quarter. The date for release of fourth quarter 2001 financial results will be January 30.

If you are unable to participate during the live webcast, the call will be archived at http://www.videonewswire.com/event.asp?id=1709. A link to this site will also be located on the company's website. In addition, an archived recording of the call can be accessed via telephone from 8 p.m. ET on October 31 through Thursday, November 15, 2001, midnight ET. Simply dial 402-530-9316 from any telephone.

(Minimum requirements to listen to web broadcast are: RealPlayer software, downloadable free from www.real.com/products/player/index.html; and at least a 28.8 kbps connection to the Internet. If you experience problems listening to the broadcast, send an e-mail to webmaster@vdat.com.)

Transgenomic is headquartered in Omaha, Neb., and has offices in the United States, Europe and Japan. Major research and development facilities are located in San Jose, Calif., and Crewe, Cheshire, United Kingdom. The company provides innovative research tools to the genomics segment of the life sciences industry. These tools enable researchers to discover and understand variation in the human genetic code, or genome, in order to accelerate and improve drug development and diagnostics.

For more information about the innovative genomics research tools developed and marketed by Transgenomic, please visit the company's website at www.transgenomic.com.